ABT-263 is orally bioavailable and has been studied in multiple clinical trials for chronic lymphocytic leukemia, lymphoma, and solid tumors (25), and its primary limiting toxicity has been thrombocytopenia because platelets rely on BCL-XL to survive (34). The gene discussed is BCL2L1; the disease is Thrombocytopenia.